|
|
|
|
||
Sorafenib cancer treatment performance improves in HCCcarcinoma by M1/M2 reprogammingA study out of China pointing to sorafenib cancer treatment performance improves in
hepatocellular carcinoma
by reprogramming M1/M2 in TAMS. Sorafenib is chemotherapy brand is Nexavar
|
return to message board, top of board |